DENVER & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of preclinical studies in support of the ongoing clinical evaluation of its oral investigational mTOR inhibitor, deforolimus, in patients with non-small cell lung cancer and certain other solid tumors. These findings, which are being presented by scientists from ARIAD’s partner, Merck & Co., Inc., at the annual meeting of the American Association for Cancer Research (AACR), provide further evidence of mTOR as a validated cancer target with potential clinical applicability in several different tumor types.
